platelet-derived growth factor receptor, or PDGFR, colony-stimulating factor 1 receptor, and c-KIT inhibitor. The company is currently conducting a Phase 3 clinical trial called the PROSERA Study ...

0% RR in pts who did not receive sargramostim as adjuvant Cohort II: 12 pts had decrease in PSA (median decline, 32%); 1 pt had >99 ... macrophage colony-stimulating factor; BCG = bacillus ...

Niktimvo, an anti-colony stimulating factor 1 receptor (CSF-1R) antibody, has received approval in the US for treating chronic GVHD in adult and paediatric patients weighing a minimum of 40kg ...

Emactuzumab, a humanized immunoglobulin G1 monoclonal antibody, targets the CSF-1 receptor and inhibits macrophages in tumor tissue.

an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication ...

and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R ...

Syndax Pharmaceuticals, Inc.’s SNDX share price has dipped by 16.84%, which has investors questioning if this is right time to buy.

caused by excessive colony stimulating factor-1 (CSF-1) protein production. Emactuzumab is a humanized immunoglobulin G1 monoclonal antibody that targets the CSF-1 receptor and inhibits macrophage ...